This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Connolly, K. M. Articles by Kaplan, A. M. Search for Related Content PubMed PubMed Citation Articles by Connolly, K. M. Articles by Kaplan, A. M.

Decreased Immunosuppression Associated with Antitumor Activity of 5-Deoxy-5-fluorouridine Compared to 5-Fluorouracil and 5-Fluorouridine¹

Departments of Surgery and Microbiology [K. M. C.], Pharmacology [R. D. A., R. B. D.], and Medicine [R. B. D.], Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, 23298 and Department of Medical Microbiology and Immunology [A. M. K.], University of Kentucky College of Medicine, Lexington, Kentucky 40536-0084

5-Fluorouracil (5-FUra), 5-deoxy-5-fluorouridine (5'dFUrd), and 5-fluorouridine were compared for their relative antitumor activity, their capacity to inhibit leukocyte exudation and macrophage (MØ) killing of tumor cells in vivo and in vitro, and their ability to induce leukopenia and monocytopenia. 5'dFUrd was less toxic than 5-FUra and exhibited anti-Ehrlich ascites activity over a wider range of drug doses. Inflammatory exudates induced by thioglycollate or pyran were inhibited up to 91% by prior 5-FUra injection but were inhibited not more than 62% by 5'dFUrd. Pyran-induced MØ inhibition of Ehrlich ascites proliferation in vivo was diminished up to 5-fold by 5-FUra but was never diminished more than 2-fold by 5'dFUrd, while neither agent suppressed in vitro MØ cytotoxicity of in vivo pyran-activated MØ. At high doses, 5-FUra reduced white blood cell counts 73%, in contrast to the 8% reduction caused by 5'dFUrd, while at their optimal anti-Ehrlich ascites doses, 5-FUra and 5'dFUrd both lowered white blood cell counts by only 20%. However, 5-FUra caused a severe monocytopenia not seen in animals given injections of comparable doses of 5'dFUrd. Therefore, 5-FUra appeared to inhibit the inflammatory response and antitumor activity by inhibiting the influx of immature MØ into the peritoneal cavity, not by inhibiting the function of mature effector cells.

¹ This study was supported in part by Grants CA 28308 and CA 23412 from the USPHS and a grant from the National Foundation for Cancer Research.

² Recipient of a postdoctoral fellowship (CA 06648) from the National Cancer Institute. Present address: Immunopharmacology, Sterling-Winthrop Research Institute, Rensselaer, N.Y. 12144.

³ Present address: Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, Conn. 06510

⁴ To whom requests for reprints should be addressed.

Received 10/27/82. Accepted 2/10/83.

This article has been cited by other articles:

				L. D. Recht and J. M. Primavera Case 24-1999- Neurologic Disorder in a 65-Year-Old Man after Treatment of Colon Cancer N. Engl. J. Med., August 12, 1999; 341(7): 512 - 519. [Full Text] [PDF]